Blog

Global markets are demanding higher standards of drug safety, efficacy and quality. The pharmaceutical industry is facing unprecedented regulatory complexity.

The 15th European Statistical Forum in Bergamo brought together experts to discuss Master Protocols for faster drug development, combining scientific innovation with networking and cultural experiences.

A comprehensive regulatory submission represents months or years of development work, millions of dollars in investment, and ultimately, the pathway to bringing new treatments to patients.

Artificial intelligence and machine learning are fundamentally transforming regulatory affairs in the pharmaceutical and medical device industries.

For pharmaceutical companies pursuing global market access, understanding the differences between the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is fundamental to strategic success.

Understanding how to register a drug in Europe is essential for any pharmaceutical company seeking to bring innovative treatments to patients across the European Union. The European regulatory system, while harmonized in many aspects, presents unique challenges and opportunities that require careful strategic planning and execution.

Roche's clinical operations team reduced study start-up time by 35% after implementing specialized GCP training that addressed real-world site management challenges. Their previous generic compliance training covered regulatory requirements but missed the practical skills needed to handle investigator queries, manage protocol deviations, and coordinate multi-site data collection efficiently.

In the rapidly evolving Life Science industry, technical expertise alone is no longer sufficient for career advancement and organizational success. As pharmaceutical companies navigate complex regulatory landscapes, biotechnology firms accelerate innovation cycles, and medical device manufacturers adapt to emerging technologies, the demand for professionals who can effectively manage change while maintaining scientific rigor has never been higher. The ability to lead transformation initiatives, communicate complex scientific concepts across diverse stakeholder groups, and adapt to shifting market dynamics has become a critical differentiator in today's competitive landscape.

In today's tight-regulation era of the pharmaceutical sector, product quality and patient safety are more than questions of good conscience—they're issues of rigid adherence to standards of manufacture approved. Good Manufacturing Practices (GMP) form the basis of pharmaceutical quality control, an encompassing system controlling every process from raw material handling to finished product release.

Medical device companies that employ targeted training programs experience 31% shorter regulatory review times and 40% fewer compliance problems. The performance gap between trained and untrained employees emphasizes the value of targeted education in an industry in which precision determines patient safety as well as business success.

Wearable devices, mobile apps, algorithms, and digital therapeutics are reshaping the rules of clinical research. But what do terms like Digital Endpoints or Digital Therapeutics really mean? And how ready is Italy to adopt these technologies in a widespread, validated, and regulated way? We asked to professionals with international experience in the sector, to help us explore what true innovation means in the world of digital clinical research.

The scientific communication landscape continues to evolve, with research papers maintaining their position as the primary vehicle for disseminating new knowledge. Understanding how to develop and structure these essential documents has become increasingly crucial for professionals seeking to contribute to the scientific discourse and advance their careers in life sciences.